Antiretroviral therapy and management of HIV infection
- PMID: 20609987
- DOI: 10.1016/S0140-6736(10)60676-9
Antiretroviral therapy and management of HIV infection
Abstract
Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Antiretroviral drugs in HIV-infected children.Pharmacol Res. 2011 Jul;64(1):1-3. doi: 10.1016/j.phrs.2011.01.007. Epub 2011 Jan 19. Pharmacol Res. 2011. PMID: 21255650 Review.
-
Current status and challenges of antiretroviral research and therapy.Antiviral Res. 2010 Jan;85(1):25-33. doi: 10.1016/j.antiviral.2009.10.007. Epub 2009 Dec 16. Antiviral Res. 2010. PMID: 20018390 Review.
-
Treatment interruption in HIV therapy: a SMART strategy?Infection. 2006 Jun;34(3):186-8. doi: 10.1007/s15010-006-6306-y. Infection. 2006. PMID: 16804667
-
Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.AIDS. 1999 Sep;13 Suppl 1:S49-59. AIDS. 1999. PMID: 10546785 Review.
Cited by
-
Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold.ChemMedChem. 2013 Jan;8(1):112-7. doi: 10.1002/cmdc.201200411. Epub 2012 Nov 23. ChemMedChem. 2013. PMID: 23180603 Free PMC article.
-
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.Pharm Res. 2012 Apr;29(4):972-82. doi: 10.1007/s11095-011-0637-9. Epub 2011 Dec 9. Pharm Res. 2012. PMID: 22161308
-
Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis.HIV Clin Trials. 2011 Jul-Aug;12(4):190-200. doi: 10.1310/hct1204-190. HIV Clin Trials. 2011. PMID: 22044855 Free PMC article. Clinical Trial.
-
Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients.Adolesc Health Med Ther. 2011 Sep 14;2:85-93. doi: 10.2147/AHMT.S11177. eCollection 2011. Adolesc Health Med Ther. 2011. PMID: 24600277 Free PMC article. Review.
-
EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment.PLoS Pathog. 2018 Jun 7;14(6):e1007061. doi: 10.1371/journal.ppat.1007061. eCollection 2018 Jun. PLoS Pathog. 2018. PMID: 29879225 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical